Thermo Fisher Scientific (TMO) Receivables - Net (2009 - 2026)

Thermo Fisher Scientific has disclosed Receivables - Net across 18 years of filings, most recently posting $9.2 billion for Q1 2026.

• Quarterly Receivables - Net rose 8.86% year-over-year to $9.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 billion (up 8.86% YoY) and the FY2025 annual result came in at $8.9 billion, up 8.66% from the prior year.
• Receivables - Net climbed to $9.2 billion in Q1 2026, from $8.9 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $9.2 billion in Q1 2026 and troughed at $7.7 billion in Q4 2022.
• A 5-year average of $8.3 billion and a median of $8.2 billion in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net jumped 42.04% — and 2024, when it retreated 1.37%.
• Tracing TMO's Receivables - Net over 5 years: stood at $8.1 billion in 2022, then advanced by 1.31% to $8.2 billion in 2023, then retreated by 0.36% to $8.2 billion in 2024, then climbed by 8.66% to $8.9 billion in 2025, then rose by 3.42% to $9.2 billion in 2026.
• Business Quant data shows TMO's Receivables - Net at $9.2 billion in Q1 2026, $8.9 billion in Q4 2025, and $8.9 billion in Q3 2025.